Ray Fang, PhD

Dr. Fang has led multiple small molecule drug development projects from preclinical to phase I clinical study. He also has ample experience in therapeutic antibody engineering and pharmacology study. Before joining in Systems Oncology, he was a Director of Biology and Drug Discovery at FronThera Pharmaceuticals (FTP), where he supervised all internal and external R&D function from target due diligence, lead screening, pharmacology, ADME-PK, and exploratory toxicology, to preclinical IND study in multiple therapeutic areas, and supported phase I clinical study. Prior to joining FTP, he has developed several bispecific immune checkpoint blockers for melanoma, breast and ovarian cancer, and long-lasting insulins for Diabetes at California Institute for Biomedical Research (Calibr). Part of his translational research was published in PNAS. Before working for Calibr, he helped launch the US branch of HD Biosciences (now a Wuxi Apptec company), setting up small molecule screening instrumentation and developing various cell-based assays.

Dr. Fang received his PhD from Shanghai Institute of Biochemistry and Cell Biology, and completed his postdoctoral training in Sanford Burnham Prebys Medical Discovery Institute (SBP). He can be reached at rfang@systemsoncology.com